focus -WSS

focus

author：Wikipedia 2025-08-23 18:39:11 - browse：7

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： At Orexo, a ‘turning point’ for everything but digital health

WSS

Testing for cancer recurrence creates a new limbo for patients

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Readout Newsletter: What happened with Sarepta's Duchenne data

At Orexo, a ‘turning point’ for everything but digital health

In early work, researchers turn to CRISPR to treat Alzheimer's

Biden tests positive for Covid

hotspot

focus

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Biden's order seeks to regulate AI risk without stifling innovation

Guidelines to prevent youth baseball injuries need more muscle

Senate panel to vote on hospitals, PBMs, prisoner care

At least 13 dead in Texas as scorching temps continue

Biden's order seeks to regulate AI risk without stifling innovation

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Telehealth options flood the market as retailers push virtual care

As demand for Covid shots wanes, Moderna seeks its next success

Emergency medicine has repudiated 'excited delirium.' Now what?

focus

Why hospitals are withdrawing from US News rankings

Cosmetics set for new safety regulation. Why the industry is on board

Diversifying clinical trials isn't enough to close racial gaps: study

Paying for Covid pills will soon shift to insurers

Biden tests positive for Covid

Doctors find melanoma drugs effective against rare brain cancer

focus

hotspot

leisure time

Wikipedia